Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
183 stopped studies mapped to Diffuse Large B-Cell Lymphoma and descendants · 88% state a reason
Over the 183 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing… | Phase 2 | terminated | Dec 23, 2014 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | new study | Other (stated, no rule matched) |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell… | Phase 1 / Phase 2 | terminated | Jul 2, 2017 | Acerta Pharma BV | Sponsor's decision not to pursue further development of the combination in DLBCL | Sponsor / business decision |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large… | Phase 1 | terminated | Jul 26, 2011 | Novartis Pharmaceuticals | Study terminated due to enrolment challenges and availability of other options for DLBCL patients.… | Safety / toxicity |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator,…(Javelin DLBCL) | Phase 3 | terminated | Nov 1, 2016 | Pfizer | Study was terminated due to closure of study arms following futility analysis and difficulty in… | Efficacy / futility |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating… | Phase 1 | terminated | Jun 26, 2015 | Fred Hutchinson Cancer Center | Closed early due to lack of funding | Funding |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | N/A | withdrawn | Aug 7, 2020 | Wake Forest University Health Sciences | Principal investigator decided not to pursue trial | Investigator |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | — | withdrawn | Mar 3, 2020 | George Washington University | Study never started due to COVID pandemic and lack of study funding. | COVID-19 / pandemic |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by… | Phase 1 / Phase 2 | terminated | Jul 21, 2017 | The Lymphoma Academic Research Organisation | Stop of drug development | Other (stated, no rule matched) |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory… | Phase 2 | terminated | Feb 21, 2013 | Gilead Sciences | Study was terminated due to safety measures. | Safety / toxicity |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | Phase 2 | withdrawn | Oct 25, 2018 | Brown University | lack of funding | Funding |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy,… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2018 | M.D. Anderson Cancer Center | Lack of Funding | Funding |
| NCT03670901 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With… | Phase 3 | terminated | Sep 14, 2018 | JHL Biotech, Inc. | The development was stopped due to company's strategy consideration | Sponsor / business decision |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or… | Phase 1 | terminated | Jun 15, 2018 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP… | Phase 3 | terminated | Feb 1, 2011 | Hoffmann-La Roche | The study was closed by the Sponsor according to the protocol-specified minimum post-treatment… | Other (stated, no rule matched) |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in… | Phase 2 | terminated | Aug 4, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | Phase 1 | terminated | Apr 28, 2017 | Dana-Farber Cancer Institute | slow accrual | Enrollment / accrual |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and… | Phase 1 | withdrawn | Nov 21, 2017 | Gilead Sciences | The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the… | Other (stated, no rule matched) |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With… | Phase 2 | terminated | Jun 11, 2009 | Weill Medical College of Cornell University | The study was terminated early due to lack of accrual. | Enrollment / accrual |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated… | Phase 1 / Phase 2 | withdrawn | Aug 29, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | Phase 1 | terminated | Mar 8, 2016 | Seagen Inc. | not stated | Not stated |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT02420210 | Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell… | Phase 2 | terminated | Apr 17, 2015 | University of Chicago | Trials was stopped early due to lack of funding. | Funding |
| NCT00482053 | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation… | Phase 2 | terminated | Jun 4, 2007 | Stanford University | Low accrual | Enrollment / accrual |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT02488512 | Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse…(itTRIOlym) | Phase 2 | terminated | Jul 2, 2015 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | critical low recruitment rate | Enrollment / accrual |
| NCT02530125 | Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma… | Phase 2 | terminated | Aug 20, 2015 | Northwestern University | sponsor decided to discontinue development of the study drug. | Sponsor / business decision |
| NCT02366663 | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL(SPINOZA) | Phase 3 | terminated | Feb 19, 2015 | City of Hope Medical Center | Withdrawal of sponsor support | Other (stated, no rule matched) |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa,…(R²-DHAP) | Phase 1 / Phase 2 | terminated | Dec 6, 2016 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Phase II: no scientific interests are given anymore | Other (stated, no rule matched) |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large…(ABC-102) | Phase 1 / Phase 2 | withdrawn | Sep 3, 2014 | RedHill Biopharma Limited | Study was discontinued due to lack of recruitment. | Enrollment / accrual |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell… | Phase 1 | terminated | Mar 7, 2016 | UNC Lineberger Comprehensive Cancer Center | Lack of funding | Funding |
| NCT02815397 | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma(DLBCL) | Phase 2 | terminated | Jun 28, 2016 | Rush University Medical Center | Poor accrual | Enrollment / accrual |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | Phase 1 | withdrawn | Nov 3, 2015 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | not stated | Not stated |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory…(S-BR) | Phase 2 | withdrawn | Dec 8, 2015 | University of Arizona | Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study… | Enrollment / accrual |
| NCT01282476 | Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | terminated | Jan 25, 2011 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT00645359 | Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large…(dMRI) | — | terminated | Mar 27, 2008 | University of Michigan Rogel Cancer Center | Insufficient resources to evaluate pilot, second to shift in research priorities | Other (stated, no rule matched) |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Sep 17, 2009 | Anne Beaven, MD | The toxicity seemed to outweigh the benefit. | Safety / toxicity |
| NCT02653989 | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jan 13, 2016 | Medivation, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 22, 2021source: clinicaltrials